Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced BRAF Mutant Cancers × binimetinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 7 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Neoplasm Metastasis 2 Lung Neoplasms 2 Gastrointestinal Stromal Tumors 2 Colorectal Neoplasms 2 Solid Tumors Harboring a BRAF V600 Mutation 1 Solid Tumor 1 Soft Tissue Neoplasms 1 Recurrence 1 Pancreatic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1 Advanced BRAF Mutant Cancers 1

Interventions

encorafenib 1 binimetinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03843775 2024-10-21

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed

17 enrolled 9 charts

Advanced BRAF Mutant Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡